Davenport & Co’s Boston Scientific BSX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-10,749
| Closed | -$675K | – | 1363 |
|
|
2026
Q1 | $675K | Sell |
10,749
-3,863
| -26% | -$309K | ﹤0.01% | 838 |
|
|
2025
Q4 | $1.39M | Sell |
14,612
-328
| -2% | -$32.2K | 0.01% | 615 |
|
|
2025
Q3 | $1.46M | Buy |
14,940
+1,332
| +10% | +$138K | 0.01% | 597 |
|
|
2025
Q2 | $1.46M | Sell |
13,608
-49
| -0.4% | -$4.96K | 0.01% | 591 |
|
|
2025
Q1 | $1.38M | Buy |
13,657
+1,828
| +15% | +$184K | 0.01% | 572 |
|
|
2024
Q4 | $1.06M | Buy |
11,829
+561
| +5% | +$49.4K | 0.01% | 629 |
|
|
2024
Q3 | $944K | Sell |
11,268
-6
| -0.1% | -$473 | 0.01% | 650 |
|
|
2024
Q2 | $868K | Buy |
11,274
+2,467
| +28% | +$181K | 0.01% | 649 |
|
|
2024
Q1 | $603K | Buy |
8,807
+34
| +0.4% | +$2.19K | ﹤0.01% | 752 |
|
|
2023
Q4 | $507K | Buy |
8,773
+22
| +0.3% | +$1.17K | ﹤0.01% | 766 |
|
|
2023
Q3 | $462K | Hold |
8,751
| – | – | ﹤0.01% | 751 |
|
|
2023
Q2 | $473K | Sell |
8,751
-671
| -7% | -$35K | ﹤0.01% | 757 |
|
|
2023
Q1 | $471K | Sell |
9,422
-728
| -7% | -$34.3K | ﹤0.01% | 738 |
|
|
2022
Q4 | $470K | Sell |
10,150
-15,076
| -60% | -$653K | ﹤0.01% | 715 |
|
|
2022
Q3 | $977K | Buy |
25,226
+14,641
| +138% | +$587K | 0.01% | 498 |
|
|
2022
Q2 | $395K | Sell |
10,585
-288
| -3% | -$11.7K | ﹤0.01% | 739 |
|
|
2022
Q1 | $482K | Sell |
10,873
-728
| -6% | -$31.6K | ﹤0.01% | 745 |
|
|
2021
Q4 | $493K | Sell |
11,601
-933
| -7% | -$39.2K | ﹤0.01% | 758 |
|
|
2021
Q3 | $544K | Sell |
12,534
-2,178
| -15% | -$96.4K | ﹤0.01% | 698 |
|
|
2021
Q2 | $629K | Buy |
14,712
+3,708
| +34% | +$156K | ﹤0.01% | 589 |
|
|
2021
Q1 | $425K | Sell |
11,004
-3,940
| -26% | -$149K | ﹤0.01% | 567 |
|
|
2020
Q4 | $537K | Buy |
14,944
+256
| +2% | +$9.23K | 0.01% | 504 |
|
|
2020
Q3 | $561K | Sell |
14,688
-595
| -4% | -$22.9K | 0.01% | 438 |
|
|
2020
Q2 | $537K | Sell |
15,283
-1,094
| -7% | -$39.4K | 0.01% | 448 |
|
|
2020
Q1 | $534K | Buy |
16,377
+110
| +0.7% | +$4.3K | 0.01% | 389 |
|
|
2019
Q4 | $736K | Buy |
16,267
+949
| +6% | +$39.7K | 0.01% | 396 |
|
|
2019
Q3 | $658K | Hold |
15,318
| – | – | 0.01% | 398 |
|
|
2019
Q2 | $658K | Sell |
15,318
-605
| -4% | -$23.3K | 0.01% | 397 |
|
|
2019
Q1 | $611K | Buy |
15,923
+5,135
| +48% | +$196K | 0.01% | 384 |
|
|
2018
Q4 | $381K | Buy |
10,788
+2,248
| +26% | +$81.5K | 0.01% | 456 |
|
|
2018
Q3 | $329K | Buy |
8,540
+2,192
| +35% | +$76.6K | ﹤0.01% | 529 |
|
|
2018
Q2 | $208K | Buy |
+6,348
| New | +$191K | ﹤0.01% | 644 |
|
Other funds holding BSX
Davenport & Co's BSX Position: Q2 2026 in Review
Davenport & Co sold out of Boston Scientific (BSX) in Q2 2026, closing a stake of 10,749 shares — an estimated $675K sold.
Davenport & Co first reported a position in BSX in Q2 2018 and held it in 32 quarters. The position peaked at $1.46M in Q2 2025. 1,470 funds tracked by Wall St. Rank hold BSX as of Q2 2026.
- Davenport & Co reported no remaining Boston Scientific position as of Q2 2026 after selling out during the quarter.
- Davenport & Co sold 10,749 Boston Scientific shares in Q2 2026, an estimated $675K.
- Davenport & Co first reported a position in Boston Scientific in Q2 2018 and held it in 32 quarters.
- Davenport & Co's Boston Scientific position peaked at $1.46M in Q2 2025.
- 1,470 funds tracked by Wall St. Rank held Boston Scientific as of Q2 2026.
Based on Davenport & Co's 13F filing for Q2 2026, filed 13 Jul 2026.